NeuroRestore

What NeuroRestore does

NeuroRestore is a research, innovation, and treatment center headquartered in Lausanne, Switzerland, with an additional engineering presence at Campus Biotech in Geneva. Founded in December 2019, it is jointly operated by EPFL, the Lausanne University Hospital (CHUV), and the University of Lausanne (UNIL), with the Defitech Foundation as a founding financial supporter. The center is co-directed by neuroscientist Grégoire Courtine (EPFL) and neurosurgeon Jocelyne Bloch (CHUV) and employs a 70+ member multidisciplinary team of principal investigators, postdocs, PhD students, and clinical staff. Its mission is to develop and clinically translate implantable neurotechnologies that restore neurological function in patients with spinal cord injury, Parkinson's disease, stroke, and traumatic brain injuries. The portfolio spans the Brain-Spine Interface (wireless digital bridge), STIMO-BRIDGE activity-dependent epidural stimulation, Electronic Dura Mater (e-dura) soft implants, the Neuroprosthetic Baroreflex for hemodynamic control, Hypothalamic Deep Brain Stimulation, ARCEX non-invasive therapy, and the Tabulae Paralytica molecular atlases of spinal cord injury. AI/ML capabilities, including motor-intention decoding, closed-loop EMG/video optimization, and single-cell transcriptomic analysis via the Augur method, are embedded across the technology stack.

As a research center rather than a commercial entity, NeuroRestore is funded primarily through foundation grants (Defitech), institutional support from EPFL/CHUV/UNIL, and collaborative agreements. Pricing is not applicable. The go-to-market motion is event-driven: therapies are validated through clinical trials at CHUV and international partner hospitals (Netherlands, Canada, France), with commercialization of the brain-spine interface channeled exclusively through ONWARD Medical, a spin-off from EPFL, in partnership with CEA and supported by the European Innovation Council. Patient recruitment occurs via clinical trial waiting lists, and the center reaches the medical community through top-tier academic publications (Nature, Science, Nature Medicine), scientific conferences, and earned media. End beneficiaries are patients with paralysis, Parkinson's, stroke, and TBI; downstream commercial customers are rehabilitation clinics that will deploy approved therapies following regulatory clearance.

Name

NeuroRestore

Legal name

NeuroRestore

Website

https://neurorestore.swiss

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

101–250 employees

Short description

NeuroRestore is a Lausanne-based research center, jointly operated by EPFL, CHUV, and UNIL, that develops implantable neurotechnologies (brain-spine interfaces, epidural stimulation, neuroprosthetic systems) to restore neurological function in patients with spinal cord injury, Parkinson's, stroke, and traumatic brain injury.

Ownership category

akta.pro rank

Product category

Neurotechnology Research and Clinical Trials

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Neural & Spinal Cord Regeneration (HLAAAGAI)

akta.pro secondary industries

Neurologic Rehabilitation Centers (Stroke/TBI/SCI/MS/Parkinson’s) (HLADAJAH), Neurorehabilitation Centers (HLAFAFAH)

Keywords

• Spinal cord stimulation
• Brain-spine interface
• Neuroprosthetic therapy
• Neurological rehabilitation
• Epidural stimulation

Headquarters

HQ city

Vaud

HQ country

Switzerland

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Research Grants and Foundation Funding: NeuroRestore operates as a research center funded by foundations (Defitech Foundation) and institutional support from EPFL, CHUV, and UNIL

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

NeuroRestore is a research, innovation, and treatment center that develops and applies bioengineering strategies involving neurosurgical interventions to restore neurological functions. Its core offering comprises implantable neurotechnologies and clinical programs — including epidural spinal stimulation systems, brain-spine interfaces, neuroprosthetic baroreflex, and hypothalamic deep brain stimulation — validated through rigorous preclinical and clinical studies in patients with spinal cord injury, Parkinson's disease, stroke, and traumatic brain injuries.

Product overview

NeuroRestore is a research and innovation center spanning EPFL, CHUV, and UNIL that develops and applies medical therapies aimed at restoring neurological functions. The organization integrates implantable neurotechnologies with innovative treatments developed through rigorous preclinical and clinical studies. Their core technology portfolio includes the STIMO clinical program using targeted epidural spinal stimulation (TESS), the Brain-Spine Interface (digital bridge) for restoring natural movement control, ARCEX Therapy for non-invasive tetraplegia treatment, the Parkinson's Spinal Neuroprosthesis, the Neuroprosthetic Baroreflex for blood pressure control, and Hypothalamic Deep Brain Stimulation. These developments have led to breakthroughs for treating paraplegia, tetraplegia, Parkinson's disease, stroke, and traumatic brain injuries.

Differentiator

Problem solved

Functional benefit

Products and services

• Brain-Spine Interface (Digital Bridge) Wireless digital bridge between the brain and spinal cord that decodes cortical motor intentions and translates them into epidural spinal cord stimulation sequences, enabling paralyzed patients to walk, stand, and control movement naturally. Targeted at patients with chronic spinal cord injury participating in clinical trials.
• STIMO (STImulation Movement Overground) Clinical feasibility program delivering targeted epidural spinal stimulation (TESS) at specific locations synchronized with intended leg movements to restore motor functions in patients with chronic spinal cord injury.
• Parkinson's Spinal Neuroprosthesis Closed-loop spinal cord neuroprosthesis targeting dorsal root entry zones to reproduce natural spatiotemporal activation of lumbosacral spinal cord during walking, working synergistically with subthalamic nucleus deep brain stimulation to alleviate gait deficits, freezing of gait, and falls in patients with advanced Parkinson's disease.
• ARCEX Therapy Non-invasive spinal cord electrical stimulation therapy applied externally over the cervical spinal cord during structured rehabilitation sessions to improve arm and hand functions in people with chronic tetraplegia.
• Neuroprosthetic Baroreflex Implantable closed-loop system that uses biomimetic epidural electrical stimulation to restore hemodynamic stability, regulate blood pressure, and treat autonomic dysreflexia in patients with spinal cord injury.
• Hypothalamic Deep Brain Stimulation (DBSLH) Deep brain stimulation therapy targeting lateral hypothalamus neurons to augment walking recovery after incomplete spinal cord injury through reorganization of lumbar-terminating projections.
• Hemodynamic Stability System Implantable system that uses biomimetic epidural electrical stimulation targeting the last three thoracic spinal segments to regulate blood pressure, treat hypotensive complications, and safely manage autonomic dysreflexia in spinal cord injury patients.
• Rehabilitation Robotics Integration Combined therapy platform that integrates the implantable spinal cord neuroprosthesis with rehabilitation robotics for robot-assisted walking and cycling, enabling neurological improvements and outdoor recreational activities for spinal cord injury patients.

Quantifiable outcome

• 9 patients recovered walking ability with EES and neurorehabilitation, with improvements persisting even when stimulation was turned off
• +4 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability10 records

Feature8 records

Partnerships

Eight partnerships are on record, tiered minor and core.

• Inserm and University of BordeauxminorStrategic or Co-development Partner · 6 November 2023Collaborated on development of spinal cord neuroprosthesis for Parkinson's disease gait deficits
• Wyss Center for Bio and NeuroengineeringminorStrategic or Co-development Partner · 21 September 2023Wyss Center provides facilities and support, with Mark Anderson serving as scientist at the center while also directing CNS Regeneration at NeuroRestore
• UCLA and Harvard Medical SchoolminorStrategic or Co-development Partner · 21 September 2023Collaborated on single-cell nuclear RNA sequencing research to identify neuronal subpopulations involved in spinal cord repair
• CEA (French Alternative Energies and Atomic Energy Commission)coreTechnology or Integration · 24 May 2023CEA developed the WIMAGINE® brain recording devices and BCI algorithms, providing the brain-computer interface technology that decodes cortical signals for the brain-spine interface
• ONWARD MedicalcoreStrategic or Co-development Partner · 1 December 2019ONWARD Medical is developing a commercial version of the brain-spine interface digital bridge technology in partnership with CEA and EPFL, with support from the European Innovation Council (EIC) to make the technology available worldwide
• Sint Maartenskliniek (Netherlands)minorStrategic or Co-development Partner · 18 September 2019International clinical collaborator for hemodynamic stability research after spinal cord injury
• Radboudumc (Netherlands)minorStrategic or Co-development Partner · 18 September 2019International clinical collaborator for spinal cord injury research
• University of Calgary (Canada)minorStrategic or Co-development Partner · 18 September 2019International collaborator from Canada contributing to hemodynamic research and autonomic dysreflexia studies

Scale indicators5 records

Recent moves7 records

Expansion highlights6 records

Emerging players

• Paradromics: Paradromics develops high-data-rate implantable brain-computer interfaces targeting motor and communication restoration. It operates in the same intracortical BCI category as NeuroRestore's brain-spine interface for paralysis.
• Synchron: Synchron develops a minimally invasive endovascular brain-computer interface for paralysis patients, pursuing motor-restoration use cases that overlap with NeuroRestore's spinal cord stimulation work. It represents a less invasive alternative approach in adjacent BCI territory.
• InBrain Neuroelectronics: InBrain Neuroelectronics develops graphene-based neural interfaces for brain stimulation and recording in neurological disorders. It shares NeuroRestore's pursuit of novel electrode materials and neuromodulation therapies.
• Motif Neurotech: Motif Neurotech develops minimally invasive brain stimulation devices for mental health and neurological indications. While its lead focus differs, it represents an emerging peer in the implantable/wearable neurotechnology space adjacent to NeuroRestore's stimulation work.
• Blackrock Neurotech: Blackrock Neurotech builds implantable neural interfaces for motor and communication restoration in paralysis and other neurological conditions. It shares NeuroRestore's focus on intracortical recording and motor decoding for movement rehabilitation.

Others

• EPFL (École Polytechnique Fédérale de Lausanne): EPFL is NeuroRestore's founding academic institution and houses Grégoire Courtine's lab. It provides research infrastructure, engineering talent, and the broader neuroscience/engineering ecosystem that underpins NeuroRestore's work.
• Kessler Foundation: Kessler Foundation is a U.S. nonprofit conducting neurorehabilitation research for spinal cord injury, brain injury, and stroke. It pursues overlapping clinical translation goals in SCI motor recovery, providing a non-profit research center comparator.
• Wyss Center for Bio and Neuroengineering: The Wyss Center is a Geneva-based neurotechnology translational research facility that collaborates directly with NeuroRestore (Mark Anderson holds dual roles). It provides infrastructure and engineering support for similar neural interface and rehabilitation projects.

Direct peers

• ONWARD Medical: ONWARD Medical is an EPFL spin-off commercializing epidural electrical stimulation therapies for spinal cord injury, including technology developed with Courtine and Bloch. It is NeuroRestore's designated commercialization partner and pursues overlapping SCI restoration indications.

Broad incumbents

• Neuralink: Neuralink develops high-bandwidth implantable brain-computer interfaces aimed at restoring motor and sensory function in paralysis. While broader in ambition and much better capitalized, it competes in the same motor-restoration BCI space as NeuroRestore's brain-spine interface.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks4 records

Key highlights6 records

Customer concentration

• Xx.com/_NeuroRestore
• LinkedInlinkedin.com/company/neurorestore

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NeuroRestore